$IMRX Q3 '26 Earnings Results & Recap Immuneering expects existing cash, cash equivalents and marketable securities as of September 30, 2026 to fund development and operations into fourth quarter of 2028, shortened from 2029.
$IMRX Q3 '26 Earnings Results & Recap Immuneering expects existing cash, cash equivalents and marketable securities as of September 30, 2026 to fund development and operations into fourth quarter of 2028, shortened from 2029.